Phaseline

Companies › Qurient

Qurient: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 1; Oncology, Respiratory; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Adrixetinib (Q702)
Axl/Mer/CSF1R selective tyrosine kinase inhibitor
AXL, MER, CSF1RPhase 1Esophageal Cancer; Chronic Graft-Versus-Host DiseaseDec 2027
Q901
Highly selective CDK7 inhibitor
CDK7Phase 1Advanced Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05394103Q901Phase 1Advanced CancerOncologyDec 2025
NCT05438420Adrixetinib (Q702)Phase 1Esophageal CancerOncologyDec 2027
NCT07138196Adrixetinib (Q702)Phase 1Chronic Graft-Versus-Host DiseaseRespiratoryOct 2029

Targets

CDK7 (1) AXL (1) MER (1) CSF1R (1)

Companies with the same targets

Daiichi Sankyo Beijing Scitech-Mq Pharmaceuticals Astellas Xuanzhu Biopharmaceutical Syndax Pharmaceuticals SynOx Therapeutics Incyte Turning Point Therapeutics Deciphera Pharmaceuticals Merck KGaA

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.